+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update



Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update



Progres en Urologie 19(Suppl. 1): S15-S19



Indications for hormonotherapy in prostate cancer are in deep mutation and are constantly evolving. Used initially (1941) in metastatic stages, hormone therapy is used nowadays in locally advanced prostate cancer and aggressive localized disease. Its prescription in association with radiotherapy or surgery has provided a benefit regarding survival free progression. The place of hormone therapy in localized prostate cancer is not well defined and the debate is still ongoing, especially in case of biochemical recurrence after irradiation or radical prostatectomy and even in neoadjuvant cases. Additional and further studies are ongoing and are strongly needed to establish new guidelines. Nevertheless, hormone therapy is not restricted any more to palliative cases and is part of the current therapeutic arsenal of the urologist for high risk localized and/or locally advanced prostate cancers.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054307071

Download citation: RISBibTeXText

PMID: 19465332

DOI: 10.1016/s1166-7087(09)73901-6


Related references

Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer. Progres en Urologie 17(2): 235-239, 2007

Castration in the treatment of locally advanced or metastatic prostate cancer. La Revue du Praticien 63(4): 509-510, 2013

Quality of life after medical versus surgical castration for locally advanced or metastatic prostate cancer. The Journal of Sexual Medicine 15(7): S285-S286, 2018

Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer. Therapeutic Advances in Urology 7(3): 125-134, 2015

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology 33(5): 447-456, 1998

A Randomised Comparison of ‘Casodex’ Tm (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer. European Urology 33(5): 447-456, 1998

Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?. Archivio Italiano di Urologia, Andrologia 89(4): 282-286, 2018

Prostate cancer management: 2. An update on locally advanced and metastatic disease. Postgraduate Medical Journal 79(937): 643-645, 2003

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. Bju International 98(3): 563-572, 2006

Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 18(2): 163-173, 2013

ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease. Urology 82(2): 394-399, 2013

Update on options for treatment of metastatic castration-resistant prostate cancer. Oncotargets and Therapy 3: 39-51, 2010

Current treatment of locally advanced and metastatic prostate cancer. Wiener Medizinische Wochenschrift 161(15-16): 377-381, 2012

Innovations in hormonal treatment for locally advanced and/or metastatic prostate cancer. Progres en Urologie 21(Suppl. 3): S96-101, 2011

Radiation therapy for the treatment of locally advanced and metastatic prostate cancer. Hematology/Oncology Clinics of North America 15(3): 423-443, 2001